Fielder Capital Group LLC Invests $841,000 in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Fielder Capital Group LLC purchased a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 2,493 shares of the medical equipment provider’s stock, valued at approximately $841,000.

Several other large investors have also recently added to or reduced their stakes in the company. WCM Investment Management LLC acquired a new stake in shares of Intuitive Surgical in the fourth quarter valued at approximately $575,536,000. International Assets Investment Management LLC raised its position in shares of Intuitive Surgical by 32,360.5% during the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock worth $231,721,000 after acquiring an additional 684,749 shares during the last quarter. Alphinity Investment Management Pty Ltd lifted its stake in shares of Intuitive Surgical by 113.2% during the fourth quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock valued at $430,525,000 after acquiring an additional 677,455 shares during the period. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in Intuitive Surgical in the third quarter worth about $178,667,000. Finally, Quadrature Capital Ltd raised its holdings in Intuitive Surgical by 466.2% during the 3rd quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock worth $99,601,000 after purchasing an additional 280,480 shares during the last quarter. 83.64% of the stock is owned by institutional investors.

Insider Buying and Selling at Intuitive Surgical

In other news, President David J. Rosa sold 80,710 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $389.28, for a total value of $31,418,788.80. Following the completion of the transaction, the president now owns 163,399 shares of the company’s stock, valued at $63,607,962.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Intuitive Surgical news, President David J. Rosa sold 80,710 shares of Intuitive Surgical stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $389.28, for a total transaction of $31,418,788.80. Following the transaction, the president now directly owns 163,399 shares of the company’s stock, valued at approximately $63,607,962.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Marshall Mohr sold 108,790 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the transaction, the vice president now owns 26,877 shares of the company’s stock, valued at $10,349,795.16. The disclosure for this sale can be found here. Insiders have sold 228,637 shares of company stock worth $88,483,248 over the last quarter. Corporate insiders own 0.80% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on ISRG shares. StockNews.com cut shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Truist Financial lifted their price objective on Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 24th. Piper Sandler raised their target price on Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a report on Friday, April 19th. Wells Fargo & Company increased their price target on shares of Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a research report on Friday, January 19th. Finally, Barclays boosted their price objective on shares of Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a report on Thursday, January 25th. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average price target of $396.17.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG traded up $5.60 during trading hours on Tuesday, hitting $388.65. 932,707 shares of the stock were exchanged, compared to its average volume of 1,608,281. The company’s fifty day simple moving average is $385.29 and its two-hundred day simple moving average is $351.11. The company has a market cap of $137.86 billion, a PE ratio of 69.79, a price-to-earnings-growth ratio of 4.93 and a beta of 1.39. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The business’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.00 earnings per share. As a group, sell-side analysts expect that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.